Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug

Ildikó Szabó, Marilena Manea, Erika Orbán, A. Csámpai, Sz. Bősze, Rita Szabó, Miguel Tejeda, D. Gaál, Bence Kapuvári, Michael Przybylski, F. Hudecz, G. Mező

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Here, we report on the synthesis and biological properties of a conjugate in which daunorubicin (Dau) as chemotherapeutic agent was attached through an oxime bond to gonadotropin-releasing hormone-III (GnRH-III) as targeting moiety. In vitro toxicity and the cytostatic effect of the conjugate on MCF-7 human breast and C26 murine colon cancer cell lines were determined, and the results were compared with those obtained for the free daunorubicin, as well as with the doxorubicin containing derivative. In vivo antitumor effect of daunorubicin-GnRH-III was studied on Balb/c female mice transplanted with C26 tumor. Our data indicate that the daunorubicin-GnRH-III conjugate had a lower toxic effect than the free daunorubicin and it was essentially nontoxic up to 15 mg (Dau content)/kg body weight. The treatment of the C26 tumor bearing mice with the conjugate led to tumor growth inhibition and longer survival time in comparison with the controls and with the administration of the free drug. When mice were treated twice with the conjugate (on days 4 and 7 after tumor transplantation), 46% tumor growth inhibition was obtained. In this case, the increase of the median survival time was 38% compared to the controls.

Original languageEnglish
Pages (from-to)656-665
Number of pages10
JournalBioconjugate Chemistry
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 15 2009

Fingerprint

Daunorubicin
Oximes
Tumors
Pharmaceutical Preparations
Neoplasms
Bearings (structural)
Survival
Poisons
Cytostatic Agents
Toxicity
Growth
Doxorubicin
Colonic Neoplasms
Cells
gonadotropin-releasing hormone-III
Gonadotropin-Releasing Hormone
Derivatives
Breast
Transplantation
Body Weight

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Organic Chemistry
  • Pharmaceutical Science
  • Biomedical Engineering
  • Pharmacology

Cite this

Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. / Szabó, Ildikó; Manea, Marilena; Orbán, Erika; Csámpai, A.; Bősze, Sz.; Szabó, Rita; Tejeda, Miguel; Gaál, D.; Kapuvári, Bence; Przybylski, Michael; Hudecz, F.; Mező, G.

In: Bioconjugate Chemistry, Vol. 20, No. 4, 15.04.2009, p. 656-665.

Research output: Contribution to journalArticle

Szabó, Ildikó ; Manea, Marilena ; Orbán, Erika ; Csámpai, A. ; Bősze, Sz. ; Szabó, Rita ; Tejeda, Miguel ; Gaál, D. ; Kapuvári, Bence ; Przybylski, Michael ; Hudecz, F. ; Mező, G. / Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. In: Bioconjugate Chemistry. 2009 ; Vol. 20, No. 4. pp. 656-665.
@article{27c5fa927432450d8d8dcaee521c75b1,
title = "Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug",
abstract = "Here, we report on the synthesis and biological properties of a conjugate in which daunorubicin (Dau) as chemotherapeutic agent was attached through an oxime bond to gonadotropin-releasing hormone-III (GnRH-III) as targeting moiety. In vitro toxicity and the cytostatic effect of the conjugate on MCF-7 human breast and C26 murine colon cancer cell lines were determined, and the results were compared with those obtained for the free daunorubicin, as well as with the doxorubicin containing derivative. In vivo antitumor effect of daunorubicin-GnRH-III was studied on Balb/c female mice transplanted with C26 tumor. Our data indicate that the daunorubicin-GnRH-III conjugate had a lower toxic effect than the free daunorubicin and it was essentially nontoxic up to 15 mg (Dau content)/kg body weight. The treatment of the C26 tumor bearing mice with the conjugate led to tumor growth inhibition and longer survival time in comparison with the controls and with the administration of the free drug. When mice were treated twice with the conjugate (on days 4 and 7 after tumor transplantation), 46{\%} tumor growth inhibition was obtained. In this case, the increase of the median survival time was 38{\%} compared to the controls.",
author = "Ildik{\'o} Szab{\'o} and Marilena Manea and Erika Orb{\'a}n and A. Cs{\'a}mpai and Sz. Bősze and Rita Szab{\'o} and Miguel Tejeda and D. Ga{\'a}l and Bence Kapuv{\'a}ri and Michael Przybylski and F. Hudecz and G. Mező",
year = "2009",
month = "4",
day = "15",
doi = "10.1021/bc800542u",
language = "English",
volume = "20",
pages = "656--665",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug

AU - Szabó, Ildikó

AU - Manea, Marilena

AU - Orbán, Erika

AU - Csámpai, A.

AU - Bősze, Sz.

AU - Szabó, Rita

AU - Tejeda, Miguel

AU - Gaál, D.

AU - Kapuvári, Bence

AU - Przybylski, Michael

AU - Hudecz, F.

AU - Mező, G.

PY - 2009/4/15

Y1 - 2009/4/15

N2 - Here, we report on the synthesis and biological properties of a conjugate in which daunorubicin (Dau) as chemotherapeutic agent was attached through an oxime bond to gonadotropin-releasing hormone-III (GnRH-III) as targeting moiety. In vitro toxicity and the cytostatic effect of the conjugate on MCF-7 human breast and C26 murine colon cancer cell lines were determined, and the results were compared with those obtained for the free daunorubicin, as well as with the doxorubicin containing derivative. In vivo antitumor effect of daunorubicin-GnRH-III was studied on Balb/c female mice transplanted with C26 tumor. Our data indicate that the daunorubicin-GnRH-III conjugate had a lower toxic effect than the free daunorubicin and it was essentially nontoxic up to 15 mg (Dau content)/kg body weight. The treatment of the C26 tumor bearing mice with the conjugate led to tumor growth inhibition and longer survival time in comparison with the controls and with the administration of the free drug. When mice were treated twice with the conjugate (on days 4 and 7 after tumor transplantation), 46% tumor growth inhibition was obtained. In this case, the increase of the median survival time was 38% compared to the controls.

AB - Here, we report on the synthesis and biological properties of a conjugate in which daunorubicin (Dau) as chemotherapeutic agent was attached through an oxime bond to gonadotropin-releasing hormone-III (GnRH-III) as targeting moiety. In vitro toxicity and the cytostatic effect of the conjugate on MCF-7 human breast and C26 murine colon cancer cell lines were determined, and the results were compared with those obtained for the free daunorubicin, as well as with the doxorubicin containing derivative. In vivo antitumor effect of daunorubicin-GnRH-III was studied on Balb/c female mice transplanted with C26 tumor. Our data indicate that the daunorubicin-GnRH-III conjugate had a lower toxic effect than the free daunorubicin and it was essentially nontoxic up to 15 mg (Dau content)/kg body weight. The treatment of the C26 tumor bearing mice with the conjugate led to tumor growth inhibition and longer survival time in comparison with the controls and with the administration of the free drug. When mice were treated twice with the conjugate (on days 4 and 7 after tumor transplantation), 46% tumor growth inhibition was obtained. In this case, the increase of the median survival time was 38% compared to the controls.

UR - http://www.scopus.com/inward/record.url?scp=65249179433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249179433&partnerID=8YFLogxK

U2 - 10.1021/bc800542u

DO - 10.1021/bc800542u

M3 - Article

C2 - 19296605

AN - SCOPUS:65249179433

VL - 20

SP - 656

EP - 665

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 4

ER -